{
    "organizations": [],
    "uuid": "65b2d4016f0d6018501ddb4d69e5c761364a90ad",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sun-pharmaceutical-industries-says/brief-sun-pharmaceutical-industries-says-u-s-fda-issued-form-483-with-3-observations-for-halol-facility-idUSFWN1QD0JG",
    "ord_in_thread": 0,
    "title": "BRIEF-Sun Pharmaceutical Industries Says U.S. FDA Issued Form 483 With 3 Observations For Halol Facility",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 23 (Reuters) - Sun Pharmaceutical Industries Ltd :\n* SUN PHARMACEUTICAL INDUSTRIES -U.S. FDA CONDUCTED GMP INSPECTION OF HALOL FACILITY (GUJARAT, INDIA) FROM FEBRUARY 12-23, 2018\n* AT CONCLUSION OF INSPECTION, AGENCY ISSUED A FORM 483, WITH THREE OBSERVATIONS\n* SUN PHARMACEUTICAL INDUSTRIES - CO PREPARING RESPONSE TO FDA OBSERVATIONS, TO BE SUBMITTED WITHIN 15 BUSINESS DAYS Source text - bit.ly/2EXxdbY Further company coverage:\n ",
    "published": "2018-02-23T16:59:00.000+02:00",
    "crawled": "2018-02-24T13:25:00.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "sun",
        "pharmaceutical",
        "industry",
        "ltd",
        "sun",
        "pharmaceutical",
        "industry",
        "fda",
        "conducted",
        "gmp",
        "inspection",
        "halol",
        "facility",
        "gujarat",
        "india",
        "february",
        "conclusion",
        "inspection",
        "agency",
        "issued",
        "form",
        "three",
        "observation",
        "sun",
        "pharmaceutical",
        "industry",
        "co",
        "preparing",
        "response",
        "fda",
        "observation",
        "submitted",
        "within",
        "business",
        "day",
        "source",
        "text",
        "company",
        "coverage"
    ]
}